Further evidence that E-cadherin is not a tumour suppressor gene in invasive ductal carcinoma of the breast: An immunohistochemical study

Histopathology

Volumn 62, Issue 5, 2013, Pages 695-701

  Rakha, Emad A ^a   Teoh, Tsu K ^a   Lee, Andrew H S ^a   Nolan, Chris C ^a   Ellis, Ian O ^a   Green, Andrew R ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Biology; Breast cancer; E cadherin expression; Immunohistochemistry

Indexed keywords

BETA CATENIN; CDH1 ANTIBODY; EOSIN; HECD 1 ANTIBODY; HEMATOXYLIN; PROTEIN ANTIBODY; PROTEIN P120; UNCLASSIFIED DRUG; UVOMORULIN;

AGED; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STAINING;

AGED; BETA CATENIN; BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL MEMBRANE; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MULTIPROTEIN COMPLEXES; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 84875576976     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12066     Document Type: Article

References (65)

1. Sommers CL, Thompson EW, Torri JA, Kemler R, Gelmann EP, Byers SW. Cell adhesion molecule uvomorulin expression in human breast cancer cell lines: relationship to morphology and invasive capacities. Cell Growth Differ. 1991; 2; 365-372.
2. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66; 107-119.
3. Handschuh G, Candidus S, Luber B et al. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 1999; 18; 4301-4312.
4. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim. Biophys. Acta 1994; 1198; 11-26.
5. Oka H, Shiozaki H, Kobayashi K et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993; 53; 1696-1701.
6. Sarrio D, Perez-Mies B, Hardisson D et al. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 2004; 23; 3272-3283.
7. Golenhofen N, Drenckhahn D. The catenin, p120ctn, is a common membrane-associated protein in various epithelial and non-epithelial cells and tissues. Histochem. Cell Biol. 2000; 114; 147-155.
8. Ozawa M. P120-independent modulation of E-cadherin adhesion activity by the membrane-proximal region of the cytoplasmic domain. J. Biol. Chem. 2003; 278; 46014-46020.
9. Berx G, Cleton-Jansen AM, Nollet F et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 1995; 14; 6107-6115.
10. Huiping C, Sigurgeirsdottir JR, Jonasson JG et al. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. Br. J. Cancer 1999; 81; 1103-1110.
11. Berx G, Cleton-Jansen AM, Strumane K et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996; 13; 1919-1925.
12. Rakha EA, Patel A, Powe DG et al. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am. J. Surg. Pathol. 2010; 34; 1472-1479.
13. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int. J. Cancer 2001; 92; 404-408.
14. Dabbs DJ, Bhargava R, Chivukula M. Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin. Am. J. Surg. Pathol. 2007; 31; 427-437.
15. Roylance R, Droufakou S, Gorman P et al. The role of E-cadherin in low-grade ductal breast tumorigenesis. J. Pathol. 2003; 200; 53-58.
16. Cleton-Jansen AM. E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res. 2002; 4; 5-8.
17. Gillett CE, Miles DW, Ryder K et al. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J. Pathol. 2001; 193; 433-441.
18. Charpin C, Garcia S, Bouvier C et al. E-cadherin quantitative immunocytochemical assays in breast carcinomas. J. Pathol. 1997; 181; 294-300.
19. Lipponen P, Saarelainen E, Ji H, Aaltomaa S, Syrjanen K. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer. J. Pathol. 1994; 174; 101-109.
20. Goldstein NS. Does the level of E-cadherin expression correlate with the primary breast carcinoma infiltration pattern and type of systemic metastases? Am. J. Clin. Pathol. 2002; 118; 425-434.
21. Heimann R, Lan F, McBride R, Hellman S. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res. 2000; 60; 298-304.
22. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am. J. Clin. Pathol. 1996; 105; 394-402.
23. Elzagheid A, Kuopio T, Ilmen M, Collan Y. Prognostication of invasive ductal breast cancer by quantification of E-cadherin immunostaining: the methodology and clinical relevance. Histopathology 2002; 41; 127-133.
24. Hirayama R, Nihei Z, Osanai T et al. [Expression of E-cadherin as related to prognostic factors and survivals in breast cancer]. Nihon Rinsho 1995; 53; 1613-1618.
25. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 2005; 46; 685-693.
26. Abd El-Rehim DM, Ball G, Pinder SE et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int. J. Cancer 2005; 116; 340-350.
27. Rakha EA, Putti TC, Abd El-Rehim DM et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J. Pathol. 2006; 208; 495-506.
28. Pereira H, Pinder SE, Sibbering DM et al. Pathological prognostic factors in breast cancer. IV: should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995; 27; 219-226.
29. Elston CW, Ellis IO. The breast. In Elston C, Ellis I eds. Systemic pathology. Edinburgh: Churchill Livingstone, 1998; 239-249.
30. Rakha EA, El-Sayed ME, Lee AH et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J. Clin. Oncol. 2008; 26; 3153-3158.
31. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 1992; 20; 479-489.
32. Lakhani SR, Rakha EA, Simpson P. World Health Organization (WHO) classification of tumours of the breast, 4th edn. Lyon: IARC Press, 2012; 40-42.
33. Dillon DA, D'Aquila T, Reynolds AB, Fearon ER, Rimm DL. The expression of p120ctn protein in breast cancer is independent of alpha- and beta-catenin and E-cadherin. Am. J. Pathol. 1998; 152; 75-82.
34. Asgeirsson KS, Jonasson JG, Tryggvadottir L et al. Altered expression of E-cadherin in breast cancer. Patterns, mechanisms and clinical significance. Eur. J. Cancer 2000; 36; 1098-1106.
35. Strathdee G. Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin. Cancer Biol. 2002; 12; 373-379.
36. Graff JR, Herman JG, Lapidus RG et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995; 55; 5195-5199.
37. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl Acad. Sci. USA 1995; 92; 7416-7419.
38. Battle E, Sancho E, Franci C et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2000; 2; 84-89.
39. Pierceall WE, Woodard AS, Morrow JS, Rimm D, Fearon ER. Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines. Oncogene 1995; 11; 1319-1326.
40. De Leeuw WJ, Berx G, Vos CB et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J. Pathol. 1997; 183; 404-411.
41. Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ et al. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology 2002; 40; 536-546.
42. Rieger-Christ KM, Pezza JA, Dugan JM, Braasch JW, Hughes KS, Summerhayes IC. Disparate E-cadherin mutations in lcis and associated invasive breast carcinomas. Mol. Pathol. 2001; 54; 91-97.
43. Shibata T, Kokubu A, Sekine S, Kanai Y, Hirohashi S. Cytoplasmic p120ctn regulates the invasive phenotypes of E-cadherin-deficient breast cancer. Am. J. Pathol. 2004; 164; 2269-2278.
44. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am. J. Clin. Pathol. 2001; 115; 85-98.
45. Moll R, Mitze M, Frixen UH, Birchmeier W. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am. J. Pathol. 1993; 143; 1731-1742.
46. Mahler-Araujo B, Savage K, Parry S, Reis-Filho JS. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J. Clin. Pathol. 2008; 61; 615-620.
47. Gould Rothberg BE, Bracken MB. E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res. Treat. 2006; 100; 139-148.
48. Come C, Arnoux V, Bibeau F, Savagner P. Roles of the transcription factors snail and slug during mammary morphogenesis and breast carcinoma progression. J. Mammary Gland Biol. Neoplasia 2004; 9; 183-193.
49. Logullo AF, Nonogaki S, Pasini FS, Osorio CA, Soares FA, Brentani MM. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression. Oncol. Rep. 2010; 23; 313-320.
50. Kovacs A, Dhillon J, Walker RA. Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas. Mol. Pathol. 2003; 56; 318-322.
51. Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod. Pathol. 2003; 16; 79-84.
52. Fons G, Hasibuan SM, van der Velden J, ten Kate FJ. Validation of tissue microarray technology in endometrioid cancer of the endometrium. J. Clin. Pathol. 2007; 60; 500-503.
53. Wärnberg F, Amini R-M, Goldman M, Jirström K. Quality aspects of the tissue microarray technique in a population-based cohort with ductal carcinoma in situ of the breast. Histopathology 2008; 53; 642-649.
54. Ruiz C, Seibt S, Al Kuraya K et al. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int. J. Cancer 2006; 118; 2190-2194.
55. Packeisen J, Buerger H, Krech R, Boecker W. Tissue microarrays: a new approach for quality control in immunohistochemistry. J. Clin. Pathol. 2002; 55; 613-615.
56. Kumar B, De Silva M, Venter DJ, Armes JE. Tissue microarrays: a practical guide. Pathology 2004; 36; 295-300.
57. Aleskandarany M, Green A, Rakha E, Mohammed R, Paish E, Ellis I. Mib1 tumour growth fraction assessment in lymph node negative breast cancer. J. Pathol. 2008; 216; S9.
58. Rakha EA, El-Sayed ME, Green AR et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J. Clin. Oncol. 2007; 25; 4772-4778.
59. Lancashire L, Powe D, Rakha E et al. Neural networks identify gene profiles that predict clinical outcome with high accuracy in breast cancer: Ca ix is identified as the principal prognostic indicator. J. Pathol. 2008; 216; S49.
60. Hecht JL, Kotsopoulos J, Gates MA, Hankinson SE, Tworoger SS. Validation of tissue microarray technology in ovarian cancer: results from the nurses' health study. Cancer Epidemiol. Biomark. Prev. 2008; 17; 3043-3050.
61. Boone J, van Hillegersberg R, van Diest PJ, Offerhaus GJ, Rinkes IH, Kate FJ. Validation of tissue microarray technology in squamous cell carcinoma of the esophagus. Virchows Arch. 2008; 452; 507-514.
62. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 2000; 80; 1943-1949.
63. Kleer CG, van Golen KL, Braun T, Merajver SD. Persistent E-cadherin expression in inflammatory breast cancer. Mod. Pathol. 2001; 14; 458-464.
64. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 2003; 5; R217-R222.
65. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006; 9; 261-272.